AKIN GUMP STRAUSS HAUER & FELD

Lobbying for KYVERNA THERAPEUTICS, INC. · Biopharmaceutical company focused on developing cell therapies for autoimmune diseases.

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · California · House · Senate · $50,000.00 income · posted Jan 20, 2026

Lobbying activity 1

Health Issues

Issues related to developing cell therapies for patients, including Stiff Person Syndrome, rare disease, and multiple sclerosis.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.